Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium223Insight biomarker and immune response study in mCRPC
NL-OMON55470Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Feb 2019
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Open-label, single-arm trial of radium-223 dichloride in prostate cancer (PCa), sponsored by Erasmus MC. Primary endpoints: Exploratory biomarker analysis versus failure-free survival, Total alkaline phosphatase decline and 10 more. Started Feb 2019; status: active, not recruiting.
02
Drugs
radium-223 dichloride
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON55470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55470.